GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Growth Rank

Modalis Therapeutics (TSE:4883) Growth Rank : 0 (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Growth Rank?

Modalis Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Modalis Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Modalis Therapeutics (TSE:4883) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Growth Rank
Comparable Companies
TSE:4586 TSE:4892 TSE:4539 TSE:4597 TSE:4512 TSE:4524 TSE:4582 TSE:4574 TSE:4538 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Website
https://www.modalistx.com
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines